Teva targets $2.5B sales for Austedo in 2027 while advancing innovative portfolio

Earnings Call Insights: Teva Pharmaceutical Industries Limited (TEVA) Q1 2025

Management View

  • CEO Richard Francis highlighted that Q1 2025 marks the ninth consecutive quarter of growth for Teva, underscoring the success of its “Pivot to Growth” strategy launched in 2023. Revenue grew 5% to $3.9 billion, with

Leave a Reply

Your email address will not be published. Required fields are marked *